Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Functional Analyses
Author:
Piro Anna1ORCID, Cufaro Maria Concetta23ORCID, Lanuti Paola23ORCID, Brocco Davide4ORCID, De Lellis Laura1ORCID, Florio Rosalba1ORCID, Pilato Serena15ORCID, Pagotto Sara24ORCID, De Fabritiis Simone23ORCID, Vespa Simone2ORCID, Catitti Giulia23, Verginelli Fabio12ORCID, Simeone Pasquale23ORCID, Pieragostino Damiana26ORCID, Del Boccio Piero12ORCID, Fontana Antonella15ORCID, Grassadonia Antonino26, Di Ianni Mauro37ORCID, Cama Alessandro1ORCID, Veschi Serena1ORCID
Affiliation:
1. Department of Pharmacy, G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy 2. Center for Advanced Studies and Technology (CAST), G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy 3. Department of Medicine and Aging Sciences, G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy 4. Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy 5. UdA–TechLab, Research Center, G. d’Annunzio University of Chieti-Pescara, Via dei Vestini, 66100 Chieti, Italy 6. Department of Innovative Technologies in Medicine and Odontoiatry, G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy 7. Hematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, 65124 Pescara, Italy
Abstract
Pancreatic cancer (PC) has a poor prognosis and displays resistance to immunotherapy. A better understanding of tumor-derived extracellular vesicle (EV) effects on immune responses might contribute to improved immunotherapy. EVs derived from Capan-2 and BxPC-3 PC cells isolated by ultracentrifugation were characterized by atomic force microscopy, Western blot (WB), nanoparticle tracking analysis, and label-free proteomics. Fresh PBMCs from healthy donors were treated with PC- or control-derived heterologous EVs, followed by flow cytometry analysis of CD8+ and CD4+ lymphocytes. The proteomics of lymphocytes sorted from EV-treated or untreated PBMCs was performed, and the IFN-γ concentration was measured by ELISA. Notably, most of the proteins identified in Capan-2 and BxPC-3 EVs by the proteomic analysis were connected in a single functional network (p = 1 × 10−16) and were involved in the “Immune System” (FDR: 1.10 × 10−24 and 3.69 × 10−19, respectively). Interestingly, the treatment of healthy donor-derived PBMCs with Capan-2 EVs but not with BxPC-3 EVs or heterologous control EVs induced early activation of CD8+ and CD4+ lymphocytes. The proteomics of lymphocytes sorted from EV-treated PBMCs was consistent with their activation by Capan-2 EVs, indicating IFN-γ among the major upstream regulators, as confirmed by ELISA. The proteomic and functional analyses indicate that PC-EVs have pleiotropic effects, and some may activate early immune responses, which might be relevant for the development of highly needed immunotherapeutic strategies in this immune-cold tumor.
Funder
Italian Ministry of University and Research European Union—NextGenerationEU Italian Ministry of University
Reference44 articles.
1. Purushothaman, A., Oliva-Ramírez, J., Treekitkarnmongkol, W., Sankaran, D., Hurd, M.W., Putluri, N., Maitra, A., Haymaker, C., and Sen, S. (2023). Differential Effects of Pancreatic Cancer-Derived Extracellular Vesicles Driving a Suppressive Environment. Int. J. Mol. Sci., 24. 2. Extracellular Vesicles in Pancreatic Cancer Immune Escape: Emerging Roles and Mechanisms;Liu;Pharmacol. Res.,2022 3. Biological Properties of Extracellular Vesicles and Their Physiological Functions;Siljander;J. Extracell. Vesicles,2015 4. Simeone, P., Bologna, G., Lanuti, P., Pierdomenico, L., Guagnano, M.T., Pieragostino, D., Del Boccio, P., Vergara, D., Marchisio, M., and Miscia, S. (2020). Extracellular Vesicles as Signaling Mediators and Disease Biomarkers across Biological Barriers. Int. J. Mol. Sci., 21. 5. De Lellis, L., Florio, R., Di Bella, M.C., Brocco, D., Guidotti, F., Tinari, N., Grassadonia, A., Lattanzio, R., Cama, A., and Veschi, S. (2021). Exosomes as Pleiotropic Players in Pancreatic Cancer. Biomedicines, 9.
|
|